Assignee
IMMUNITYBIO INC
US·45 granted patents·58 pending applications·37 citations·filing 2019–2025
Top patents by PatentIndex Score
103 records- 0195US12384852B2Genetically modified NK-92 cells having a safety switchIMMUNITYBIO INC·Filed 2021·Granted Aug 12, 2025·2 cites·20 claims
- 0295US12272439B1Distributed ledger for medicament administration trackingIMMUNITYBIO INC·Filed 2024·Granted Apr 8, 2025·2 cites·32 claims
- 0395US12109238B2Chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2022·Granted Oct 8, 2024·2 cites·17 claims
- 0495US11547727B2Chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2019·Granted Jan 10, 2023·10 cites·13 claims
- 0594US12492377B2Modified NK-92 haNK003 cells for the clinicIMMUNITYBIO INC·Filed 2023·Granted Dec 9, 2025·1 cites·19 claims
- 0694US11643452B2Fc-epsilon carIMMUNITYBIO INC·Filed 2021·Granted May 9, 2023·6 cites·8 claims
- 0793US12403178B2Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)IMMUNITYBIO INC·Filed 2023·Granted Sep 2, 2025·2 cites·22 claims
- 0892US2024366674A1Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 0990US12516112B2Single-chain chimeric polypeptides and uses thereofIMMUNITYBIO INC·Filed 2024·Granted Jan 6, 2026·0 cites·20 claims
- 1090US12365874B2Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptorsIMMUNITYBIO INC·Filed 2021·Granted Jul 22, 2025·1 cites·18 claims
- 1190US2026078342A1MODIFIED NK-92 haNK003 CELLS FOR THE CLINICIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 1289US12473348B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsIMMUNITYBIO INC·Filed 2021·Granted Nov 18, 2025·1 cites·18 claims
- 1389US12473347B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsIMMUNITYBIO INC·Filed 2021·Granted Nov 18, 2025·1 cites·18 claims
- 1489US12016916B2Nant COVID vaccine cross reactivityIMMUNITYBIO INC·Filed 2023·Granted Jun 25, 2024·0 cites·20 claims
- 1588US12195520B2Advanced avatar dendritic cellsIMMUNITYBIO INC·Filed 2024·Granted Jan 14, 2025·0 cites·20 claims
- 1688US2025340664A1Genetically modified nk-92 cell lineIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 1787US12435122B2Fc-epsilon CARIMMUNITYBIO INC·Filed 2019·Granted Oct 7, 2025·3 cites·8 claims
- 1887US11813292B2Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)IMMUNITYBIO INC·Filed 2019·Granted Nov 14, 2023·2 cites·3 claims
- 1987US2025084150A1Advanced Avatar Dendritic CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 2086US12509494B2Multi-chain chimeric polypeptides and uses thereofIMMUNITYBIO INC·Filed 2022·Granted Dec 30, 2025·0 cites·9 claims
- 2186US12398186B2Multi-chain chimeric polypeptides and uses thereofIMMUNITYBIO INC·Filed 2022·Granted Aug 26, 2025·0 cites·29 claims
- 2286US12378300B2Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cellsIMMUNITYBIO INC·Filed 2020·Granted Aug 5, 2025·1 cites·19 claims
- 2386US12168052B2Nant COVID vaccine cross reactivityIMMUNITYBIO INC·Filed 2024·Granted Dec 17, 2024·0 cites·16 claims
- 2484US11911459B2Nant COVID vaccine cross reactivityIMMUNITYBIO INC·Filed 2022·Granted Feb 27, 2024·0 cites·18 claims
- 2584US2024424088A1Nant COVID Vaccine Cross ReactivityIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 2683US12180283B2Anti-B7-H4 chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2019·Granted Dec 31, 2024·1 cites·21 claims
- 2783US12064450B2Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2022·Granted Aug 20, 2024·0 cites·11 claims
- 2882US11975027B2Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2021·Granted May 7, 2024·0 cites·8 claims
- 2981US12290558B2SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogensIMMUNITYBIO INC·Filed 2023·Granted May 6, 2025·0 cites·11 claims
- 3081US2024319198A1Biological Deposit Labeling And TrackingIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3180US12274748B2Adenoviral vector transduced apheresis productIMMUNITYBIO INC·Filed 2024·Granted Apr 15, 2025·0 cites·6 claims
- 3280US11453862B2Mononuclear cell derived NK cellsIMMUNITYBIO INC·Filed 2019·Granted Sep 27, 2022·2 cites·16 claims
- 3380US2025073305A1Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)IMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3480US2025019716A1Methods And Systems For Producing A Protein Of Interest In A PlantIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3579US12043656B2Advanced avatar dendritic cellsIMMUNITYBIO INC·Filed 2022·Granted Jul 23, 2024·0 cites·17 claims
- 3678US2025170181A1Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 3778US2024002802A1Modified nk-92 cells for treating cancerIMMUNITYBIO INC·Filed 2023·Application pending·0 cites
- 3877US2025066484A1Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3977US2025115870A1Mononuclear Cell Derived NK CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4077US2025066500A1Methods of treating age-related and inflammatory diseasesIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4176US2024366972A1Chimeric Antigen Receptor-Modified NK-92 CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4276US2024252540A1Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironmentIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4375US12479899B2Multi-chain chimeric polypeptides and uses thereofIMMUNITYBIO INC·Filed 2023·Granted Nov 25, 2025·0 cites·38 claims
- 4475US2025270282A1Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cellsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 4574US12584138B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesIMMUNITYBIO INC·Filed 2021·Granted Mar 24, 2026·0 cites·13 claims
- 4674US2023272042A1Fc-epsilon carIMMUNITYBIO INC·Filed 2023·Application pending·0 cites
- 4773US12180492B2Methods and systems for producing a protein of interest in a plantIMMUNITYBIO INC·Filed 2022·Granted Dec 31, 2024·0 cites·20 claims
- 4873US2025109409A1RIG1 Inhibition and Therapeutic Viral Protein ExpressionIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4973US2025011718A1Ex Vivo Generation of Immune Effector Cells from Apheresis Material IntermediatesIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 5073US2025011380A1Methods of treating aging-related disordersIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 103 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IMMUNITYBIO INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →